Understanding PMT regulation more broadly may aid in identifying treatments that preferentially target specific subtypes, as demonstrated for CDK4/6 [21] or EZH2 [22] inhibition for proneural glioblastomas and DGKα [23] or BMI-1 [22] inhibition for mesenchymal glioblastomas. The gene discussed is EZH2; the disease is glioblastoma.